As of 2026-09-27, the Relative Valuation of Urogen Pharma Ltd (URGN) is (1.30) USD. This relative valuation is based on P/E multiples. With the latest stock price at 41.35 USD, the upside of Urogen Pharma Ltd based on Relative Valuation is -103.2%.
The range of the Relative Valuation is (0.84) - (16.03) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.4x - 9.5x | 0.7x |
| Forward P/E multiples | 0.4x - 8.0x | 0.6x |
| Fair Price | (0.84) - (16.03) | (1.30) |
| Upside | -102.0% - -138.8% | -103.2% |
| Date | P/E |
| 2026-09-23 | -20.77 |
| 2026-09-22 | -21.34 |
| 2026-09-21 | -21.56 |
| 2026-09-18 | -21.58 |
| 2026-09-17 | -21.93 |
| 2026-09-16 | -21.70 |
| 2026-09-15 | -20.83 |
| 2026-09-14 | -21.28 |
| 2026-09-11 | -21.11 |
| 2026-09-10 | -21.08 |
| 2026-09-09 | -22.45 |
| 2026-09-08 | -21.86 |
| 2026-09-04 | -22.00 |
| 2026-09-03 | -22.39 |
| 2026-09-02 | -22.17 |
| 2026-09-01 | -21.65 |
| 2026-08-31 | -21.50 |
| 2026-08-28 | -21.77 |
| 2026-08-27 | -22.70 |
| 2026-08-26 | -22.92 |
| 2026-08-25 | -23.13 |
| 2026-08-24 | -23.03 |
| 2026-08-21 | -23.38 |
| 2026-08-20 | -23.35 |
| 2026-08-19 | -25.09 |
| 2026-08-18 | -24.41 |
| 2026-08-17 | -24.52 |
| 2026-08-14 | -24.06 |
| 2026-08-13 | -24.01 |
| 2026-08-12 | -24.45 |
| 2026-08-11 | -23.51 |
| 2026-08-10 | -23.11 |
| 2026-08-07 | -23.43 |
| 2026-08-06 | -22.75 |
| 2026-08-05 | -23.17 |
| 2026-08-04 | -19.92 |
| 2026-08-03 | -19.26 |
| 2026-07-31 | -19.08 |
| 2026-07-30 | -20.50 |
| 2026-07-29 | -20.18 |
| 2026-07-28 | -20.40 |
| 2026-07-27 | -20.69 |
| 2026-07-24 | -20.44 |
| 2026-07-23 | -21.21 |
| 2026-07-22 | -20.99 |
| 2026-07-21 | -21.85 |
| 2026-07-20 | -20.52 |
| 2026-07-17 | -20.07 |
| 2026-07-16 | -19.96 |
| 2026-07-15 | -19.86 |